Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies

NEXT STORY
Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting
PREV STORY
NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Shire plc : Elections for the interim dividend in respect of the six months to December 31, 2017

Elections for the interim dividend in respect of the six months to December 31, 2017 ...

author_avatar
NASDAQ Market News

Saniona to Present at Multiple Upcoming Investor Conferences

author_avatar
NASDAQ Market News

Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity

author_avatar
NASDAQ Market News